Little is known regarding coronavirus disease 2019 (COVID-19) vaccination rates in people with HIV (PWH), a vulnerable population with significant morbidity from COVID-19. We assessed COVID-19 vaccination rates among 6952 PWH in the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) compared to region- and country-specific vaccination data. The global probability of COVID-19 vaccination through end of July 2021 was 55% among REPRIEVE participants with rates varying substantially by Global Burden of Disease (GBD) superregion. Among PWH, factors associated with COVID-19 vaccination included residence in high-income regions, age, white race, male sex, body mass index, and higher cardiovascular risk. Clinical Trials Registration. NCT02344290.

中文翻译：

---

全球 HIV 队列中的 COVID-19 疫苗接种率


对于 HIV 感染者 (PWH) 的 2019 冠状病毒病 (COVID-19) 疫苗接种率知之甚少，而 HIV 感染者是一个因 COVID-19 发病率较高的弱势群体。我们在预防 HIV 血管事件随机试验 (REPRIEVE) 中评估了 6952 名感染者的 COVID-19 疫苗接种率，并与特定地区和国家的疫苗接种数据进行了比较。截至 2021 年 7 月底，REPRIEVE 参与者中接种 COVID-19 疫苗的全球概率为 55%，不同全球疾病负担 (GBD) 大区域的比率差异很大。在感染者中，与 COVID-19 疫苗接种相关的因素包括居住在高收入地区、年龄、白种人、男性、体重指数和较高的心血管风险。临床试验注册。 NCT02344290。